Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer—Where Are We Now?

SIMPLE SUMMARY: The past decade has seen the development and regulatory approval of a large number of new treatment options for advanced prostate cancer. Despite this, the two most used treatments—abiraterone and enzalutamide—have not been surpassed in efficacy, and eventually, all patients develop...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Arpit, Moka, Nagaishwarya, Hamstra, Daniel A., Ryan, Charles J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834038/
https://www.ncbi.nlm.nih.gov/pubmed/35159068
http://dx.doi.org/10.3390/cancers14030801

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8834038/
https://www.ncbi.nlm.nih.gov/pubmed/35159068
http://dx.doi.org/10.3390/cancers14030801

Ejemplares similares